Form 4: BioCryst Pharmaceuticals Director Acquires Shares in Lieu of Cash Retainer

Director Vincent Milano acquired 750 shares of BioCryst Pharmaceuticals common stock in lieu of a portion of his quarterly cash retainer.

Summary

• Vincent Milano, a director at BioCryst Pharmaceuticals, acquired 750 shares of common stock on November 29, 2024.
• The shares were acquired at a price of $7.50 per share.
• This acquisition was in lieu of 50% of his quarterly cash board member retainer of $11,250.
• Following the transaction, Mr. Milano directly owns 76,084 shares of BioCryst Pharmaceuticals stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects a director's continued investment in the company, which is generally seen as a good sign. The transaction is routine and expected.

Positives

• The acquisition demonstrates the director's continued investment and confidence in the company.
• The use of stock in lieu of cash may be seen as a positive sign of the company's financial management.

Industry Context

This is a routine filing related to insider transactions and is common for publicly traded companies. It reflects a director's compensation and investment in the company.

Comparison to Industry Standards

• The practice of compensating board members with stock is common across the pharmaceutical industry, aligning director interests with shareholder value.
• Many companies, such as Gilead Sciences and Vertex Pharmaceuticals, also use stock-based compensation for their directors.
• The amount of stock awarded is consistent with industry norms for board member compensation.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns director interests with the company's performance.
• The use of stock instead of cash may be viewed positively by creditors and suppliers as it conserves cash.

Key Dates

Keywords

BioCryst Pharmaceuticals, BCRX, Director, Stock Acquisition, Insider Trading, Form 4, Share Ownership, Vincent Milano